Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery

Management of localized gastric cancer

(2013) Mariela A. Blum et al.   JOURNAL OF SURGICAL ONCOLOGY

Randomized Prospective Phase II Study to Compare the Combination Chemotherapy Regimen Epirubicin, Cisplatin, and 5-Fluorouracil With Epirubicin, Cisplatin, and Capecitabine in Patients With Advanced or Metastatic Gastric Cancer

(2011) Janja Ocvirk et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis

(2011) Francesco Montagnani et al.   Gastric Cancer

Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

(2011) Marc Ychou et al.   JOURNAL OF CLINICAL ONCOLOGY

18F-FDG PET-Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial

(2011) C. Meyer zum Buschenfelde et al.   JOURNAL OF NUCLEAR MEDICINE

Advanced gastric cancer – Slow but steady progress

(2010) Derek G. Power et al.   CANCER TREATMENT REVIEWS

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2010) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE